JP2008542296A5 - - Google Patents

Info

Publication number

JP2008542296A5

JP2008542296A5 JP2008513752A JP2008513752A JP2008542296A5 JP 2008542296 A5 JP2008542296 A5 JP 2008542296A5 JP 2008513752 A JP2008513752 A JP 2008513752A JP 2008513752 A JP2008513752 A JP 2008513752A JP 2008542296 A5 JP2008542296 A5 JP 2008542296A5

Authority

JP

Japan

Prior art keywords

composition

sirtuin

prodrug

modulator

analog

Prior art date

2006-05-24

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• LAMQVIQMVKWXOC-UHFFFAOYSA-N 4-methyl-n-[2-[3-(morpholin-4-ylmethyl)imidazo[2,1-b][1,3]thiazol-6-yl]phenyl]-2-pyridin-3-yl-1,3-thiazole-5-carboxamide Chemical compound CC=1N=C(C=2C=NC=CC=2)SC=1C(=O)NC1=CC=CC=C1C(N=C1SC=2)=CN1C=2CN1CCOCC1 LAMQVIQMVKWXOC-UHFFFAOYSA-N 0.000 claims 21
• 239000000203 mixture Substances 0.000 claims 21
• 239000000651 prodrug Substances 0.000 claims 14
• 229940002612 prodrug Drugs 0.000 claims 14
• 102000011990 Sirtuin Human genes 0.000 claims 9
• 108050002485 Sirtuin Proteins 0.000 claims 9
• 239000012190 activator Substances 0.000 claims 9
• 239000008194 pharmaceutical composition Substances 0.000 claims 8
• 150000003839 salts Chemical class 0.000 claims 8
• 229920000858 Cyclodextrin Polymers 0.000 claims 7
• QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims 7
• LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical group C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims 7
• 229940016667 resveratrol Drugs 0.000 claims 7
• 235000021283 resveratrol Nutrition 0.000 claims 7
• HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims 7
• JLEBZPBDRKPWTD-TURQNECASA-O N-ribosylnicotinamide Chemical group NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=C1 JLEBZPBDRKPWTD-TURQNECASA-O 0.000 claims 6
• 235000020956 nicotinamide riboside Nutrition 0.000 claims 6
• 239000011618 nicotinamide riboside Substances 0.000 claims 6
• 239000002245 particle Substances 0.000 claims 6
• 239000007788 liquid Substances 0.000 claims 5
• 230000002503 metabolic effect Effects 0.000 claims 5
• 206010047571 Visual impairment Diseases 0.000 claims 3
• 239000002207 metabolite Substances 0.000 claims 3
• 208000029257 vision disease Diseases 0.000 claims 3
• 230000004393 visual impairment Effects 0.000 claims 3
• 239000011436 cob Substances 0.000 claims 2
• 238000004090 dissolution Methods 0.000 claims 2
• HOSGXJWQVBHGLT-UHFFFAOYSA-N 6-hydroxy-3,4-dihydro-1h-quinolin-2-one Chemical group N1C(=O)CCC2=CC(O)=CC=C21 HOSGXJWQVBHGLT-UHFFFAOYSA-N 0.000 claims 1
• 230000006735 deficit Effects 0.000 claims 1
• 238000002513 implantation Methods 0.000 claims 1
• 239000008176 lyophilized powder Substances 0.000 claims 1
• 239000007909 solid dosage form Substances 0.000 claims 1
• ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 claims 1